A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis Clinical Trial

Official title:
A Single-center, Randomized, Open, Two-period, Two-sequence Crossover Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate-to-Severe Plaque Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT06182384
Study type	Interventional
Source	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Contact	Sheng Feng
Phone	+86 021-61053363
Email	sheng.feng@hengrui.com
Status	Recruiting
Phase	Phase 1
Start date	December 24, 2023
Completion date	February 5, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05787236` - A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Active, not recruiting	`NCT04612699` - A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis	Phase 2
Not yet recruiting	`NCT06258668` - Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Recruiting	`NCT06142357` - Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Recruiting	`NCT03710681` - A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis	Phase 1
Not yet recruiting	`NCT04839016` - Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis	Phase 3